FindTrial
Sign In

Tecentriq

DRUG5 trials

Sponsors

F. Hoffmann-La Roche AG, NSABP Foundation Inc., F. HOFFMANN-LA ROCHE LTD

Conditions

Locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) who have progressed following standard systemic chemotherapy (including if given in combination with anti-PD-1 therapy, after anti-PD-1 as monotherapy, or after tyrosine kinase inhibitor [TKI] therapy). NSCLCMetastatic breast cancerMetastatic non-small cell lung cancer (NSCLC)Non−Small Cell Lung CancerPatients with early breast cancerand HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC)hormone receptor positive breast cancer (HR+ BC)including triple negative breast cancer (TNBC)

Phase 1

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients with Metastatic Breast Cancer (MORPHEUS-panBC)
RecruitingCTIS2023-503629-20-00
F. Hoffmann-La Roche AGand HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC), hormone receptor positive breast cancer (HR+ BC), including triple negative breast cancer (TNBC) +1
Start: 2018-06-27Target: 50Updated: 2025-08-14
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)
CompletedCTIS2023-504038-23-00
F. Hoffmann-La Roche AGMetastatic non-small cell lung cancer (NSCLC)
Start: 2018-05-10End: 2025-04-02Target: 149Updated: 2025-02-14

Phase 3

A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (TAIL)
Active, not recruitingLBCTR2020033438
F. HOFFMANN-LA ROCHE LTDLocally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) who have progressed following standard systemic chemotherapy (including if given in combination with anti-PD-1 therapy, after anti-PD-1 as monotherapy, or after tyrosine kinase inhibitor [TKI] therapy). NSCLC
Start: 2018-04-13Target: 10Updated: 2026-02-02
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo "GeparDouze"
CompletedCTIS2023-508472-11-00
NSABP Foundation Inc.Patients with early breast cancer
Start: 2018-06-13End: 2025-11-19Target: 978Updated: 2025-08-05
A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTIPD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB-IIIA NONSMALL CELL LUNG CANCER
Active, not recruitingCTIS2023-505981-26-00
F. Hoffmann-La Roche AGNon−Small Cell Lung Cancer
Start: 2015-11-20Target: 452Updated: 2026-01-12